Biosketch

As a medical student at University of Sherbrooke, Pierre Noel was awarded the Frosst medal for being the top graduating medical student in his class. Following medical school, he completed his residency training in internal medicine at the University of Sherbrooke. Following his residency he did a fellowship in hematology at Mayo Clinic and was a Mayo Clinic Scholar at the Terry Fox Cancer Research Laboratory.

Dr. Noel became a consultant in hematology and laboratory medicine at Mayo Clinic and was later named director of the bone marrow transplantation program. He then became chair of hematology-oncology at Mayo Clinic Scottsdale.

Dr. Noel came to the NIH Clinical Center has chief of the hematology section in 2000. He is also an adjunct associate professor of medicine at the United Services University of the Health Sciences. Dr. Noel was the medical director of the NIH medical team responding to Hurricane Katrina and was the acting associate director of security and emergency response at the NIH from May to November of 2006.

Honors and Awards

NIH Director Award, 2005; NIH Clinical Center Director's Award, 2005; Secretary of Health and Human Services Award, 2006; NIH Director Award, 2007

Selected Publications

PEER REVIEWED ARTICLES

Bhanu NV, Trice TA, Lee TY, Grantt N, Oneal P, Schwartz JD, Noel P, Miller JL. A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells. Blood. 105: 387- 393, 2005.

Kreitman RJ, Squires DR, Wilson WH, Stetler-Stevenson M, Noel P, FitzGerald DJP, Pastan I. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38(BL22) in patients with B-cell malignancies. J.Clin. Oncol  23:6719-6729, 2005.

Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg JH, Reilly JT, Verstovsek S, Dupriez B, Hoffman R, Thiele J, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA, Camoriano JK, Noel P, Cross NCP, Gisslinger H, Vardiman JW, Gilliland DG, Kantajian H. International Working Group Consensus Criteria for Treatment Response in Myelofibrosis with Myeloid Metaplasia. Blood, 108:1497-503, 2006.

Kim YJ, Dale JK, Noel P, Brown M, Nuttman TB, Strauss SE, Klion AD. Eosinophilia identifies a subgroup of patients with Autoimmune Lymphoproliferative Syndrome and a high mortality rate. Am J Hematol. 82(7):615-24, 2007.

Akin C, Scott LM, Kocabas CN, Kushnir-Sukov N, Brittain E, Noel P, Metcalfe DD. Demonstration of an aberrant mast cell population with clonal markers in a subset of patients with recurrent anaphylaxis. Blood. 110:2331-1333, 2007

Robyn J, Maric I, Metcalfe DD, Fay MP, Carter M, Wilson T, Fu W, Stoddard J, Scott L. Hartsell M, Kirshenbaum A, Akin C, Nutman TB, Noel P, Klion AD. Imatinib resistant Kit D816V-associated mast cell disease with eosinophilia and imatinib sensitive FIP1L1-PDGFRA associated hypereosinophilic syndrome are two distinc entities. J Allergy Clin Immunol. 120:680-687. 2007

Lahortiga I, Akin C, Wilson T, Mentens N, Arthur DC, Maric I, Noel P, Kocabas C, Marynen P, Lessin H, Wlodarska I, Robyn J, Metcalfe DD. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Hematologica. 93:49-56, 2008

Klion A, Robyn J, Maric I, Fu W, Schmid L, Lemery S, Noel P, Law M, Hartsell M, Dunbar C, Nutman T. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA positive chronic eosinophilic leukemia: implications for optimal dosing. Blood. 110:3552-2556, 2007

Bhanu NV, Oneal PA, Gantt NM, Aerbajinai W, Noel P, Thomas CJ, Miller JL. Reversal of cytokine-mediated fetal hemoglobin expression by the adenosine derivative, SQ22536 (Submitted for publication).

Uzzaman A, Maric I, Noel P, Metcalfe DD, Carter M.C. Pediatric Onset Mastocytosis: A 20 year follow-up. (Submitted for publication).